shares in this article
^UTRECHT, Netherlands and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) —
Merus NV (https://merus.nl/). (Nasdaq: MRUS), a sector company
clinical oncology, the innovative multispecific antibody in full
length (Biclonics(®) and Triclonics(®) ), announced today that
that Bill Lundberg, MD, President and Chief Executive Officer of Merus, am
Wednesday, June 7, 2023 at 11:30 a.m. Eastern Time as part of the
participate in a fireside chat at this year’s Jefferies Healthcare Conference
The presentation will be webcast simultaneously on the company’s website at the
Investors section (https://ir.merus.nl/event-calendar) are available.
A recording of the presentation will also be available there for a limited time
period to be available.
Merus (https://merus.nl/about/) is a clinical oncology company
Company that innovative bispecific and trispecific
Developed full-length antibody therapeutics known as Multiclonics
Multiclonics(®) are manufactured using industry standard processes
manufactured. It has been observed in preclinical and clinical studies that
several characteristics of Multiclonics with the characteristics of conventional human
monoclonal antibodies are identical, e.g. B. long half-life and low
immunogenicity. Visit the Merus website for more information
(http://www.merus.nl/) and on Twitter (https://twitter.com/MerusNV).
Multiclonics(®), Biclonics(®) and Triclonics(®) are registered trademarks of
Leverage must be between 2 and 20